Hepatitis B Screening Prior to Chemotherapy in the Middle East: A Retrospective Cohort Study

Authors

  • Nathalie Ziade American University of Beirut Medical Center
  • Mohammad Hosni
  • Kassem Barada
  • Abdul Rahman Bizri

DOI:

https://doi.org/10.3823/842

Keywords:

Hepatitis B Virus, Antineoplastic Agents, Screening Tests

Abstract

Background: Hepatitis B virus (HBV) reactivation can be asymptomatic or manifest as fatal fulminant hepatitis. Most international guidelines recommend screening patients prior to immunosuppressive therapy.

Aims: To determine HBV screening rates and modalities in patients receiving chemotherapy at the American University of Beirut Medical Center.

Methods: A retrospective cohort review of electronic health records of  adult patients who received chemotherapeutic agents, between June 2015 and June 2016. Patients clinical characteristics were documented. Adequate screening was defined as performing all: HBsAg, HBs Abs, and anti HBc Abs(total).

Results: A total of 1547 patients were initially assessed. 45.6% were males with a mean age of 56. 382(30%) had hematologic malignancies, of whom 111 underwent HSCT. Of those included, 303(24%) patients were screened by at least one test for HBV and 42(3.3%) for HBsAg, anti HBc Abs and HBs Abs.

Patients who were appropriately screened were significantly younger(p=0.008) and more likely to have hematologic malignancies (n=35, 83.3%, p<0.0001). Among patients with hematologic malignancies, appropriately screened patients (n=35) were younger (p=0.042) and had a history of HSCT(n=19, 54.3%, p=0.001).

Conclusion: Rates of screening for HBV prior to chemotherapy at our medical center are low, and not always complete or adequate. There is an urgent need to implement a better screening policy.

References

Stanaway DJ, Flaxman DA, Naghavi M, Fitzmaurice C, Vos T,

Abubakar I et al. The global burden of viral hepatitis from 1990

to 2013: findings from the Global Burden of Disease Study 2013.

The Lancet. 2016; 388(10049): 1081–1088.

Ott J, Stevens G, Groeger J, Wiersma S, Global epidemiology of

hepatitis B virus infection: new estimates of age-specific HBsAg

seroprevalence and endemicity. Vaccine 2012; 30:2212-2219.

Global, regional, and national age-sex specific all-cause and

cause-specific mortality for 240 causes of death, 1990-2013:

a systematic analysis for the Global Burden of Disease Study

Crossref DOI link: https://doi.org/10.1016/S0140-

(14)61682-2

Schweitzer A, Horn J, Mikolajczyk TR, Krause G, Ott JJ.

Estimations of worldwide prevalence of chronic hepatitis B virus

infection: a systematic review of data published between 1965

and 2013. The Lancet 2015; 386:1546-1555.

Nabulsi MM, El Saleeby CM, Araj GF.The current status of

hepatitis B in Lebanon. LMJ 2003; 51: 64-70.

Specialist Panel on Chronic Hepatitis B in the Middle East. A

review of chronic hepatitis B epidemiology and management

issues in selected countries in the Middle East. J Viral Hepat

; 19: 9-22.

Kusumoto S, Tobinai K. Screening for and management of

hepatitis B virus reactivation in patients treated with anti-B-cell

therapy. ASH Education Program Book 2014; 576-583.

Lok AS, Liang RH, Chiu EK, Wong KL, Chan TK, Todd D.

Reactivation of hepatitis B virus replication in patients

receiving cytotoxic therapy: report of a prospective study.

Gastroenterology 1991; 100:182-188.

Kim SJ,Hsu C, Song YQ, Tay K, Hong XN, Cao J et al. Hepatitis

B virus reactivation in B-cell lymphoma patients treated with

rituximab: analysis from the Asia Lymphoma Study Group. Eur J

Cancer Prev 2013; 49:3486-3496.

Loomba R, Rowley A, Wesley R, Liang TJ, Hoofnagle JH, Pucino

F et al. Systematic review: the effect of preventive lamivudine on

hepatitis B reactivation during chemotherapy. Ann. Intern Med

; 148: 519-528.

Di Bisceglie AM1, Lok AS, Martin P, Terrault N, Perrillo RP,

Hoofnagle JH. Recent US Food and Drug Administration

warnings on hepatitis B reactivation with immune- suppressing

and anticancer drugs: just the tip of the iceberg? Hepatology

; 61(2):703-11

Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas

MM et al. Update on prevention, diagnosis, and treatment

of chronic hepatitis B: AASLD 2018 hepatitis B guidance.

Hepatology 2018; 67:1560-1599.

El-Sayed MH, Mohamed MM, Maina AM, Oliveri F, Brunetto

MR, Bonino F. Severe liver disease is caused by HBV rather than

HCV in children with hematological malignancies. Hematology J

, 4(5):321-327.

Reddy RK, Beavers LK, Hammond PS, Lim KL, Falck-Ytter YY.

American Gastroenterological Association Institute guideline on

the prevention and treatment of hepatitis B virus reactivation

during immunosuppressive drug therapy. Gastroenterology

; 148:215-219.

Abubakar I., Tillmann T., Banerjee A. Global, regional, and

national age-sex specific all-cause and cause-specific mortality

for 240 causes of death, 1990-2013: a systematic analysis for

the Global Burden of Disease Study 2013. The Lancet 2015;

:117-171 (2015).

Hwang JP., Fisch MJ., Lok AS, et al. Trends in hepatitis B virus

screening at the onset of chemotherapy in a large US cancer

center. BMC cancer 2013; 13: 534.

Neuss MN, Desch CE, McNiff KK, Eisenberg PD, Gesme DH,

Jacobson JO, et al. A process for measuring the quality of cancer

care: The Quality Oncology Practice Initiative. J Clin Oncol 2005;

:6233-6239.

Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, et al.

Asian-Pacific clinical practice guidelines on the management of

hepatitis B: a 2015 update. Hepatol. Int 2016; 10, 1-98.

Eupropean for the study of Liver. Clinical Practice Guidelines on

the management of hepatitis B virus infection. J Hepatol 2017;

: 370-398.

Weinbaum MC, Mast EE, Ward WJ. Recommendations for

identification and public health management of persons with

chronic hepatitis B virus infection. J. Hepatol 2009; 49:S35-S44.

Hwang PJ, A. S. Artz SA, Somerfield RM. Hepatitis B virus

screening for patients with cancer before therapy: American

Society of Clinical Oncology provisional clinical opinion update.

J Oncol Prac 2015; 11: e487-e489.

Vaughn PB, Doherty AG, Gautam S, Moss CA, Cheifetz SA.

Screening for tuberculosis and hepatitis B prior to the initiation

of anti-tumor necrosis therapy. Inflamm Bowel Dis 2011;

:1057-1063.

Hwang JP, Fisch MJ, Zhang H, et al. Low rates of hepatitis B virus

screening at the onset of chemotherapy. J Oncol Pract 2012;

(4):e32-e39.

Paul S, Shuja A, Tam I, Kim EM, Kang S, Kapulsky L, et

al.Gastroenterologists have suboptimal hepatitis B virus

screening rates in patients receiving immunosuppressive

therapy. Dig Dis Sci 2016; 61:2236-2241.

Nusair M, Rayyan Y, Hammoudeh W, et al. Hepatitis B care

pathway in Jordan: current situation, gaps and recommended

actions. J Virus Erad 2020; 6(1):1-6. 26.

Abaalkhail F , Elsiesy H, AlOmair A, Alghamdi MY, Alalwan A,

AlMasri N,et al. SASLT practice guidelines for the management

of hepatitis B virus. Saudi J Gastroenterol 2014; 20: 5-25.

J. Choi Y, Y.-S. Lim SY. Characteristics, Prevention, and

Management of Hepatitis B Virus (HBV) Reactivation in HBVInfected

Patients Who Require Immunosuppressive Therapy. Int

J InfectDis 2017; 216, S778-S784.

Lao TT, Sahota SD,. Law WL, Cheng KY, Leung YT. Age-specific

prevalence of hepatitis B virus infection in young pregnant

women, Hong Kong Special Administrative Region of China.

Bull World Health Organ 2014; B; 92:782-789.

Downloads

Published

2020-05-07

Issue

Section

Articles

Most read articles by the same author(s)